An interventional study of Screener and Standard of care in Stroke, sponsored by The University of Texas Health Science Center, Houston. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by The University of Texas Health Science Center, Houston · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Stroke by The University of Texas Health Science Center, Houston — 6 open to participants now, 9 under way, none of them phase 3. Stroke · The University of Texas Health Science Center, Houston.
Among the 39 studies in Stroke by The University of Texas Health Science Center, Houston, this one is the 7th largest by planned enrollment of the 35 interventional ones that give a count, is one of 5 that started in 2026, is one of 25 with no phase, and was the 37th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →6 of the 39 studies in Stroke by The University of Texas Health Science Center, Houston are open now, in 1 country. Recruiting first, the newest first:
The University of Texas Health Science Center, Houston · Sites in United States
Ages 55+
The University of Texas Health Science Center, Houston · Sites in United States
Ages 1+
The University of Texas Health Science Center, Houston · Sites in United States
Ages 22–65
The University of Texas Health Science Center, Houston · Sites in United States
Ages 13–21
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 4 4
First in 2001; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 21 across the 35 interventional studies, 339 across the 4 observational. Of the 30 that completed or were terminated, 13 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
The University of Texas Health Science Center, Houston is the lead sponsor of 899 studies on the registry; 214 are open to participants now.
Of its 174 completed or terminated interventional studies of FDA-regulated products, 142 (82%) have results posted.
1 of the studies in Stroke by The University of Texas Health Science Center, Houston that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06280482The University of Texas Health Science Center, HoustonNicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS) | 2027-07-25 |
Add it to your calendar (.ics) → With an account.
Among the 39 studies in Stroke by The University of Texas Health Science Center, Houston, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effectiveness of a spasticity screener and to determine if the spasticity screener results are useful to healthcare providers and impact clinical decision making
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: Screener
Other: Standard of care
Participants will be screened for spasticity using the 2 question version of the Post-stroke Spasticity Monitoring Questionnaire (PSMQ) at 2 days after discharge, 2 weeks post stroke, 1 month post stroke, 3 months post stroke and every 3 months after for a total of 12 screenings across 24 months
Observational data for the standard of care group will be obtained via phone every 3 months post stroke up to 24 months, utilizing the Standard of Care Group Questionnaire.
Time to detect spasticity from incidence of stroke
Time frame: From baseline to 24 months after stroke
Time to referral for spasticity from incidence of stroke
Evaluate average time to referral to neurology or Physical Medicine \& Rehabilitation (PM\&R)
Time frame: From baseline to 24 months after stroke
The time from incidence of stroke to Botulinum neurotoxin (BoNT) administration
Time frame: From baseline to 24 months after stroke
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Aug 2029, 37 months later.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 37 months is above that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The University of Texas Health Science Center, Houston →